Ustekinumab in the Management of Perianal Fistulizing Crohn’s Disease: Current Evidence and Practical Strategies
Drugs in R&D · 2026-06 · 26 (2) · 141-153
DOI: 10.1007/s40268-026-00545-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drugs in R&D, online erschienen am 22.05.2026. Verfasst von Bolin Yang. Beteiligte Einrichtung: Department of Colorectal Surgery/IBD Center, Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, Qinhuai District, Nanj…. Hauptthemen laut MEDLINE: Crohn Disease, Ustekinumab, Rectal Fistula. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Johnson & Johnson Innovative Medicine.
Abstract (Originalsprache)
Perianal fistulizing Crohn's disease (PFCD) is a severe and complex manifestation associated with high morbidity and limited treatment durability. Ustekinumab is a monoclonal antibody targeting the interleukin-12/23 pathway, which is involved in the pathogenesis of PFCD. Evidence from post hoc analyses and real-world studies has shown the therapeutic potential of ustekinumab in both anti-tumor necrosis factor-experienced and selected biologic-naïve patients with PFCD. Preliminary evidence has indicated that the treatment effect may be improved when used in combination with surgical interventions such as seton placement or sphincter-preserving procedures. Adjunctive antibiotics during induction and early monitoring of clinical and radiologic response may further enhance outcomes. While ustekinumab is increasingly being incorporated into multidisciplinary PFCD management, prospective fistula-specific trials are needed to clarify its optimal positioning. Future research should also focus on predictive biomarkers and treatment algorithms to support personalized and durable care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Colorectal Surgery/IBD Center, Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, Qinhuai District, Nanjing, China. yfy0051@njucm.edu.cn.
Förderung
- Johnson & Johnson Innovative Medicine
Zitieren
APA
Yang, B. (2026). Ustekinumab in the Management of Perianal Fistulizing Crohn’s Disease: Current Evidence and Practical Strategies. Drugs in R&D, 26(2), 141-153. https://doi.org/10.1007/s40268-026-00545-w
Vancouver
Yang B. Ustekinumab in the Management of Perianal Fistulizing Crohn’s Disease: Current Evidence and Practical Strategies. Drugs in R&D. 2026;26(2):141-153. doi:10.1007/s40268-026-00545-w
BibTeX
@article{Yang2026,
author = {Yang, Bolin},
title = {Ustekinumab in the Management of Perianal Fistulizing Crohn’s Disease: Current Evidence and Practical Strategies},
journal = {Drugs in R&D},
year = {2026},
volume = {26},
number = {2},
pages = {141--153},
doi = {10.1007/s40268-026-00545-w}
}
EUVIMED